Myeloid-derived suppressor sells and the efficacy of CD8+ T-cell immunotherapy
Alexander M Lesokhin1, Taha Merghoub, Jedd D Wolchok
1Memorial Sloan-Kettering Cancer Center; New York, NY USA.
Oncoimmunology
|March 26, 2013
Abstract:
Myeloid-derived suppressor cells (MDSCs) promote immune evasion, a key feature of oncogenesis. The restoration of immunosurveillance by immunomodulatory antibodies improves the survival of a subset of cancer patients. Preclinical studies suggest that the ablation of monocytic MDSCs may be a useful adjunct to available immunotherapeutic strategies against cancer.


